Indication: Rituximab was approved by the United States Food and Drug Administration (FDA) in 1997 for treatment of B cell non-Hodgkin's lymphoma.

The 2 most common rituximab protocols in Sweden are 500 and 1,000 mg every 6 months as single maintenance doses after an initial dose that may vary from 500 to ...

In an open-label, 48-week phase I trial in relapsing remitting MS, two courses of rituximab (two infusions given two weeks apart, and then repeated after 24.

8 янв. 2021 г. · The findings suggested that a single 100 mg infusion of RTX adequately depleted peripheral B cells for at least 6 weeks, with CD19+ lymphocytes ...

Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab.

19 дек. 2023 г. · Rituximab, an anti-CD20 monoclonal antibody (mAb), has led to dramatic strides in improving disease control and pathophysiologic understanding of MS.

Rituximab is given as an intravenous infusion every six months, with the most common single doses for MS being 500 mg or 1000 mg. The Swedish MS Association ...

Researchers will test if a new rituximab treatment protocol (infusion every six months) can improve clinical and MRI features of early relapsing MS.

An extended dosing interval for rituximab for patients with stable MS during the COVID-19 pandemic may be associated with a low risk of disease activity.

Most patients (89%) received rituximab at a dose of 500 mg every 6–12 months. Nine patients (11%), all with progressive MS were on 1 gm to 2 gm every 6 months.